To assess Cardiac Output Monitoring in pediatric subjects by comparing FloTrac and ClearSight system to intermittent thermodilution Swan-Ganz, in order to expand the indications of FloTrac, ClearSight and Swan-Ganz thermodilution pulmonary artery catheter to the pediatric population 12 to 18 years of age.

Inclusion Criteria:

• Subjects who are 12 to 18 years of age
• Subjects who have signed the Informed Consent Form
• Subjects who are projected to receive Swan-Ganz catheter as part of procedure/standard of care with intermittent cardiac output measures
• For those Subjects who have had a cardiac transplant,Subjects who are at least 2 weeks post cardiac transplantation
• Subjects with planned pressure monitoring with an arterial line

Exclusion Criteria:

• Subjects with contraindications for Pulmonary Artery Catheters Placement and monitoring (recurrent sepsis, or with hypercoagulopathy);
• Subjects with contraindications for Arterial Line Placement;
• Subjects with an extreme contraction of the smooth muscle in the arteries and arterioles in the lower arm and hand (i.e., Raynaud's Disease).
• Subjects with a physical site area too limited for proper Sensor placement
• Subjects with finger size less than the smallest finger cuff size
• Documented ≥ moderate pulmonary hypertension (PAPm > 25mmHg, PVRI > 3.0 WUxm2)
• Presence of intracardiac shunting (i.e., ASD, VSD)
• Aorto-pulmonary collaterals
• ≥ Moderate tricuspid regurgitation, per echocardiogram criteria
• > Moderate Aortic or pulmonary regurgitation, per echocardiogram criteria
• Persistent cardiac arrythmias during the cardiac catheterization period (> 3min)
• Vascular abnormalities of the arterial system (i.e., connective tissue disorders, mid-aortic syndrome)

Males and Females, 12 to 18 years of age at the time of screening. Who presenting to Cardiac Catheterization Lab for right heart catheterizations.

Duration of the procedure through 30 days after procedure, plus or minus 14 days